1. Home
  2. NBBK vs EVMN Comparison

NBBK vs EVMN Comparison

Compare NBBK & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBBK

NB Bancorp Inc.

HOLD

Current Price

$19.94

Market Cap

889.5M

Sector

N/A

ML Signal

HOLD

EVMN

Evommune Inc.

N/A

Current Price

$24.38

Market Cap

914.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NBBK
EVMN
Founded
1892
2020
Country
United States
United States
Employees
N/A
48
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
889.5M
914.1M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
NBBK
EVMN
Price
$19.94
$24.38
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$23.50
$43.88
AVG Volume (30 Days)
323.3K
252.4K
Earning Date
04-22-2026
06-11-2026
Dividend Yield
1.43%
N/A
EPS Growth
25.23
N/A
EPS
1.34
N/A
Revenue
N/A
N/A
Revenue This Year
$45.15
N/A
Revenue Next Year
$4.18
N/A
P/E Ratio
$14.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.44
$13.89
52 Week High
$22.86
$33.20

Technical Indicators

Market Signals
Indicator
NBBK
EVMN
Relative Strength Index (RSI) 39.73 45.33
Support Level $19.87 $21.14
Resistance Level $20.63 $25.50
Average True Range (ATR) 0.59 1.68
MACD -0.24 -0.42
Stochastic Oscillator 33.33 19.68

Price Performance

Historical Comparison
NBBK
EVMN

About NBBK NB Bancorp Inc.

NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.

About EVMN Evommune Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Share on Social Networks: